Antibody targeting of mutant calreticulin in myeloproliferative neoplasms
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.17896 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Frederike Kramer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Calreticulin, Myeloproliferative Disorders, Mutation, Receptors, Thrombopoietin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Congressionally Directed Medical Research Programs, Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Mutations in calreticulin are one of the key disease‐initiating mutations in myeloproliferative neoplasms (MPN). In MPN, mutant calreticulin translates with a novel C‐terminus that leads to aberrant binding to the extracellular domain of the thrombopoietin receptor, MPL. This cell surface neoantigen has become an attractive target for immunological intervention. Here, we summarize recent advances in the development of mutant calreticulin targeting antibodies as a novel therapeutic approach in MPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Broad Institute, Cambridge, Massachusetts, USA.
ORCID-Profile: Frederike Kramer
Förderung
- NHLBI NIH HHS
- Congressionally Directed Medical Research Programs
- Leukemia and Lymphoma Society
- Starr Cancer Consortium
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kramer, F., & Mullally, A. (2024). Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17896
Vancouver
Kramer F, Mullally A. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.17896
BibTeX
@article{Kramer2024,
author = {Kramer, Frederike and Mullally, Ann},
title = {Antibody targeting of mutant calreticulin in myeloproliferative neoplasms},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.17896}
}
EUVIMED